Skip to content
★ Sign in to follow
Shanghai Junshi Biosciences Co., Ltd. logo

Shanghai Junshi Biosciences Co., Ltd. Stock: price and insider trades · China

君实生物

CN·Mcap CN¥31.1BHealth Care

No insider purchase over the last 90 days. The latest, by 熊俊, was filed 31 Mar 2026.

Shanghai Junshi Biosciences Co., Ltd.: what insiders have been doing

Shanghai Junshi Biosciences Co., Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SSE / SZSE (CSRC). Over the twelve months to 4 November 2026, 1 filing were filed, from 1 insider.

No insider sold shares on the market over the period. Instead, the filings list 1 purchase totalling €8.7M, made by 1 insider. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 board member. The largest single trade was a purchase of €8.7M by 熊俊, published on 31 March 2026.

With 1 filing in twelve months, the company is quieter than the median of 2 filings across the 517 companies we follow on the same exchange. Since 2021, the database holds 2 purchases and no sales by insiders of the company.

The most recent open-market purchase was published on 31 March 2026, 222 days ago.

In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.

Insider Decl.
2
Thresholds
n/a
Buy Volume
€9M
2 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
熊俊1 buy

Since the insiders bought

  • Filed 31 Mar 2026 · 222 days ago · €8.7M
    -23.7%
    Entry CN¥38.40 · Close 03 Nov 2026 CN¥29.30

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Analyst consensus: bullish or bearish?

Analysts rate Shanghai Junshi Biosciences Co., Ltd. Hold (neutral), based on 1 analysts. Average price target: CN¥28.00.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 21,213 of 26,914 companies
31.6
score / 100
Value
25
Quality
38
FCF yld-4.1%
Earn yld-2.7%
EV/EBITDA·
ROE-9.3%
Gross mgn79%
Net mgn-34%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥30.31
Analyst consensus
1 analysts
Hold
CN¥28.00Target CN¥28.00(-8%)CN¥28.00
Income statement
RevenueCN¥2.5B
Gross profitCN¥2B79% margin
EBITDA-CN¥631.3M-25% margin
Net income-CN¥840.9M-14.6% margin
Valuation
PER (forward)433.0x
P/Book5.2x
Beta0.52
Balance sheet & cash
Market capCN¥31.1B
Total debtCN¥4.1B
Free Cash Flow-CN¥1.3B
Debt / Equity96%
Profitability & ownership
ROE-9.3%
ROA-2.9%
% insiders31.0%
% institutions18.9%
Last declaration on 31 March 2026
Declarations2 total
  • ▲
    董事Executives
    70M CNY15SSE
    1,999,513 shares92.0% of flowA股XSHGSSE:273000000333662850
    Canonical exit: 29 Jun 2026 (T+90)
  • ▲
    董事Executives
    6M CNY8SSE
    94,250 shares8.0% of flowA股XSHGSSE:173000005190207840
    Canonical exit: 23 Mar 2022 (T+90)

2 of 2 declarations

About Shanghai Junshi Biosciences Co., Ltd.

君实生物 is a company focused on the healthcare and pharmaceutical sector, dedicated to the research and development of innovative treatments. It is listed on the XSHG market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations